Document is current
Any future updates will be listed below
-
Authors
Chang, Tien-Ching https://orcid.org/0000-0003-0560-4930
Heard, Amanda https://orcid.org/0000-0002-7150-7998
Lattin, John
Warrington, John M. https://orcid.org/0000-0001-6066-5491
Barrett, Amanda
Landmann, Jack H.
Tenzin, Yangdon
Ganesh, Vishaal
Thompson, Bryant
Afrin, Sadia
Gupta, Deepesh Kumar
Chang, Ju-Fang
Ritchey, Julie
Selli, Mehmet Emrah https://orcid.org/0000-0002-3478-8970
Hsu, Yu-Sung
Song, Haorui https://orcid.org/0009-0005-6940-9298
Federico, A. J.
Horn, Avery
Meers, Michael P.
Weber, Evan W. https://orcid.org/0000-0001-5039-2899
Wandless, Thomas J.
Crawford, Jeremy Chase https://orcid.org/0000-0003-4096-6048
Thomas, Paul G. https://orcid.org/0000-0001-7955-0256
DiPersio, John F. https://orcid.org/0000-0002-0429-3133
Gottschalk, Stephen https://orcid.org/0000-0003-3991-7468
Singh, Nathan https://orcid.org/0000-0002-0350-7574
-
Funding
Funding for this research was provided by:
Children's Discovery Institute
Damon Runyon Cancer Research Foundation
V Foundation for Cancer Research
- License Information
-
More Information
Article History
Received: 16 January 2025
Accepted: 3 December 2025
First Online: 16 January 2026
Change Date: 9 March 2026
Change Type: Update
Change Details: This article was originally published under the subscription model but it is now published under an Open Access license.
Competing interests
: M.E.S. is currently an employee of Wugen. E.W.W. holds equity in Lyell Immunopharma and consults for Umoja Immunopharma. T.J.W. is a founder and consultant for Obsidian Therapeutics. J.F.D. receives research funding from Amphivena Therapeutics, NeoImmuneTech, Macrogenics, Incyte, Bioline Rx and Wugen; has equity ownership in Magenta Therapeutics and Wugen; consults for Incyte, RiverVest Venture Partners and hC Bioscience, Inc.; and is a board member for Magenta Therapeutics. J.C.C. and P.G.T. have patents related to cellular immunotherapy. S.G. is a co-inventor on patents and patent applications in the fields of gene and cell therapy for cancer, a member of the Scientific Advisory Board of Be Biopharma and a Data Safety Monitoring Board member of Immatics and has received honoraria from CARGO Therapeutics within the last year. N.S. holds equity in Phoreus Bio and Defiance Therapeutics and has patents and patent applications in the field of cellular immunotherapy. T.-C.C. and N.S. have submitted patent applications related to this work. The other authors declare no competing interests.
